Granulocyte colony stimulating factor is referred as stimulating factor 3, which acts to increase production of stem cells and granulocytes. Filgrastim is
a granulocyte colony stimulating factor (G-CSF) prepared by recombinant DNA
technology and often used in the treatment of low blood neutrophils. It is also
frequently used in conditions where lukapheresis with increased white blood
cells is observed. Common adverse effects of Filgrastim include joint pain,
chest pain, hair loss, and vomiting.
Filgrastim is a recombinant form of naturally occurring G-CSF and functions by stimulating neutrophil production. It was approved in the U.S. in 1991 for
the treatment low blood neutrophils. The World Health Organization declared
Filgrastim in the List of Essential Medicines as safe and most effective
medicine. Filgrastim was first discovered by Amgen, Inc. and sold under the
brand name Neupogen. Large number of biosimilar companies are engaged in the
manufacture and marketing of Filgrastim across the world. Filgrastim costs
around US$ 200 in the U.S, around GBP 50 in the U.K., and US$ 100 in developing
countries.
Filgrastim is prescribed for neutropenia, which is caused due to bone marrow transplantation and chemotherapy. It has been considered a supportive therapy in
various types of cancers. In the last decade, there has been significant
increase in cancer prophylaxis in developed countries and awareness initiatives
taken by governments to educate about early treatment. These factors are
expected to fuel the growth of the global Filgrastim market. Approved
biosimilars such as Grafeel, Colstim, Neukine, and Filcad, which are much
cheaper and readily available in developing countries, are expected to fuel the
growth of the global Filgrastim market.
Ongoing biosimilars research and strong pipeline drugs are likely to boost the growth of the global market during the forecast period. Increase in the
number of cancer patients, particularly in developing countries such as China
and India, is one of the key factors likely to propel the global Filgrastim
market during the forecast period. However, high cost of branded biologics and
stringent regulatory guidelines for the approval of biosimilars in developed
countries act as major restraints of the global market.
Request Report Brochure @? ;rep_id=45486
The global Filgrastim market can be segmented based on type, distribution channel, and region. In terms of type, the market can be bifurcated into
biologics and biosimilars. The biologics segment is expected to be driven by
high sales of established brand Neupogen. Availability of Neupogen in developing
countries and higher cost restrain the biologics segment. The biosimilars
segment is expected to expand at a higher growth rate due to low cost and easy
availability in developing countries. Based on distribution channel, the global
Filgrastim market can be categorized into hospital pharmacies, retail
pharmacies, and online pharmacies. High demand for biologics in hospitals across
the globe is projected to propel the hospital pharmacies segment from 2018 to
2026.
The global Filgrastim market can be segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa.
North America is expected to account for a major share of the global market
owing to developed health care infrastructure and favorable reimbursement
policies. Europe was the second largest market for Filgrastim in 2017. India,
China, and Japan are the major markets for Filgrastim in Asia Pacific. The
global Filgrastim market is fragmented, with presence of large number of
companies with global reach.
Request for TOC @? ;rep_id=45486
Major players in the global Filgrastim market include Amgen Inc., F. Hoffmann-La Roche Ltd., Dr. Reddy?? Laboratories Ltd, Intas Pharmaceuticals,
Cadila Pharmaceuticals, Lupin Limited, Emcure Pharmaceuticals Ltd., and Biocon.
TIANJIN, China, Oct. 9 (Xinhua) -- Following are the medalists at the 6th East Asian Games here on Wednesday:
Shooting
Men's 10m air pistol
Gold: Mai Jiajie, China
Silver: Pang Wei, China
Bronze: Wang Zhiwei, China
Men's 10m air pistol team
Gold: China
Silver: DPR Korea
Bronze: South Korea
Fencing
Women's individual epee
Gold: Sun Yujie, China
Silver: Yu Jinsil, South Korea
Bronze: Yin Mingfang, China
Bronze: Choi Injeong, South Korea
Men's individual foil
Gold: Shi Jialuo, China
Silver: Li Chen, China
Bronze: Nicholas Edward Choi, Hong Kong, China
Bronze: Kim Hyogon, South Korea
Taekwondo
Women's 49-53kg
Gold: Yoon Jeongyeon, South Korea
Silver: Oyunerdene Gansukh, Mongolia
Bronze: Lu Jingrong, Macao, China
Bronze: Lin Chiayen, Chinese Taipei
Women's 62-67kg
Gold: Park Hyemi, South Korea
Silver: Liu Qing, Macao, China
Bronze: Li Chen, China
Bronze: Chuang Chiachia, Chinese Taipei
Women's +73kg
Gold: Zheng Shuyin, China
Silver: Peng Chiahwi, Chinese Taipei
Bronze: Shin Hyeonseon, South Korea
Bronze: Wang Junnan, Macao, China
Men's 63-68kg
Gold: Lee Jooseong, South Korea
Silver: Bai Xinlong, China
Bronze: Yoshihiro Nagano, Japan
Bronze: Chuang Tzute, Chinese Taipei
Diving
Men's synchronized 3m springboard
Gold: Hiroto HasegawaYu Okamoto, Japan
Silver: Park JihoKim Jinyong, South Korea
Bronze: Li JincongCai Chengcheng, China
Women's synchronized 3m springboard
Gold: Wang XinWang Hao, China
Silver: Kim Su. Cheap Authentic Jerseys Cheap Jerseys China Free Shipping Cheap Jerseys China Wholesale Cheap NFL Jerseys Cheap Stitched NFL Jerseys Cheap Authentic NFL Jerseys Cheap NFL Nike Jerseys Wholesale Jerseys From China Wholesale Jerseys From China Wholesale NFL Jerseys
